__timestamp | BioMarin Pharmaceutical Inc. | Johnson & Johnson |
---|---|---|
Wednesday, January 1, 2014 | 302156000 | 21954000000 |
Thursday, January 1, 2015 | 402271000 | 21203000000 |
Friday, January 1, 2016 | 476593000 | 19945000000 |
Sunday, January 1, 2017 | 554336000 | 21420000000 |
Monday, January 1, 2018 | 604353000 | 22540000000 |
Tuesday, January 1, 2019 | 680924000 | 22178000000 |
Wednesday, January 1, 2020 | 737669000 | 22084000000 |
Friday, January 1, 2021 | 759375000 | 20118000000 |
Saturday, January 1, 2022 | 854009000 | 19046000000 |
Sunday, January 1, 2023 | 937300000 | 20112000000 |
Monday, January 1, 2024 | 1009025000 | 21969000000 |
Cracking the code
In the world of pharmaceuticals, understanding spending patterns can reveal much about a company's strategic priorities. Over the past decade, Johnson & Johnson and BioMarin Pharmaceutical Inc. have showcased contrasting approaches in their Selling, General, and Administrative (SG&A) expenses.
From 2014 to 2023, Johnson & Johnson consistently allocated a significant portion of its budget to SG&A, with expenses peaking at approximately $22 billion in 2018. This reflects a robust commitment to maintaining its market presence and operational efficiency. In contrast, BioMarin's SG&A expenses, while much smaller, have shown a steady increase, growing by over 200% from 2014 to 2023. This suggests a strategic expansion and investment in growth initiatives.
These spending patterns highlight the different scales and strategies of these industry leaders, offering insights into their operational priorities and market positioning.
Johnson & Johnson and Merck & Co., Inc.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Johnson & Johnson and Amgen Inc.
Breaking Down SG&A Expenses: Johnson & Johnson vs Alnylam Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Johnson & Johnson and Exelixis, Inc.
Who Optimizes SG&A Costs Better? Johnson & Johnson or Jazz Pharmaceuticals plc
Breaking Down SG&A Expenses: Johnson & Johnson vs Alkermes plc
AbbVie Inc. and BioMarin Pharmaceutical Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Bristol-Myers Squibb Company and BioMarin Pharmaceutical Inc.
Breaking Down SG&A Expenses: BioMarin Pharmaceutical Inc. vs Ultragenyx Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. vs Grifols, S.A.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and Agios Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: BioMarin Pharmaceutical Inc. vs Ligand Pharmaceuticals Incorporated